RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.

Abstract excerpt

RET gain-of-function mutations are the most common drivers in medullary thyroid carcinoma, while RET fusions are identified in 5-10% of papillary thyroid carcinomas. Thus, RET plays a major role in the tumorigenesis of thyroid neoplasia, making it a valuable therapeutic target. Over a decade ago, multikinase inhibitors (MKIs) were first shown to have variable degrees of anti-RET activity. Despite some clinical...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carcinoma, Neuroendocrine
• Share to Germ-Line Mutation
• Share to Multiple Endocrine Neoplasia Type 2a